专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

US20100112687A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB FAMILY GENE EXPRESSION AND USES THEREOF 审中-公开
标题翻译：用于抑制ERBB家族基因表达的核酸化合物及其用途
公开(公告)号：US20100112687A1
公开(公告)日：2010-05-06
申请号：US12528619
申请日：2008-02-28
申请人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Mohammad Ahmadian
发明人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Mohammad Ahmadian
IPC分类号： C12N5/071 , C07H21/02
CPC分类号： C12N15/1138 , C12N2310/14 , C12N2310/321 , C12N2310/3231 , C12N2310/3521
摘要： The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing one or more ERBB family gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to one or more ERBB family mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine and optionally other modifications or combinations thereof. Also provided are methods of decreasing expression of one or more ERBB family gene in a cell or in a subject to treat one or more ERBB family-related disease.
摘要翻译：本公开提供能够降低或沉默一种或多种ERBB家族基因表达的meroduplex核糖核酸分子（mdRNA）。本公开的mdRNA包含至少三条链，其结合形成由切口或间隙分开的至少两个不重叠的双链区域，其中一条链与一个或多个ERBB家族mRNA互补。此外，meroduplex可以具有至少一个被5-甲基尿苷取代的尿苷和任选的其它修饰或组合。还提供了降低细胞或受试者中一种或多种ERBB家族基因表达以治疗一种或多种ERBB家族相关疾病的方法。

72. 发明申请

US20100055784A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING WNT GENE EXPRESSION AND USES THEREOF 审中-公开
标题翻译：用于抑制WNT基因表达的核酸化合物及其用途
公开(公告)号：US20100055784A1
公开(公告)日：2010-03-04
申请号：US12529532
申请日：2008-03-03
申请人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Mohammad Ahmadian
发明人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Mohammad Ahmadian
IPC分类号： C12N5/071 , C07H21/02
CPC分类号： C12N15/1135 , C12N2310/14
摘要： The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing WNT1, WNT2, or WNT3A gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a WNT1, WNT2, or WNT3A mRNA. In addition, the meroduplex may have at least one uridine is a 5-methyluridine, a nucleoside is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a WNT1, WNT2, or WNT3A gene in a cell or in a subject to treat a WNT1, WNT2, or WNT3A-related disease.
摘要翻译：本公开提供能够降低或沉默WNT1，WNT2或WNT3A基因表达的meroduplex核糖核酸分子（mdRNA）。本公开的mdRNA包含至少三条链，其组合形成由切口或间隙隔开的至少两个非重叠双链区域，其中一条链与WNT1，WNT2或WNT3A mRNA互补。此外，meroduplex可以具有至少一个尿苷是5-甲基尿苷，核苷是锁定的核酸或任选的其它修饰，以及它们的任何组合。还提供减少细胞或受试者中WNT1，WNT2或WNT3A基因表达以治疗WNT1，WNT2或WNT3A相关疾病的方法。

73. 发明申请

US20100047909A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING VEGF FAMILY GENE EXPRESSION AND USES THEREOF 审中-公开
标题翻译：用于抑制VEGF家族基因表达的核酸化合物及其用途
公开(公告)号：US20100047909A1
公开(公告)日：2010-02-25
申请号：US12528508
申请日：2008-02-28
申请人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Mohammad Ahmadian
发明人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Mohammad Ahmadian
IPC分类号： C12N5/02 , C07H21/02
CPC分类号： C12N15/1136 , C12N15/1131 , C12N2310/14 , C12N2310/3231 , C12N2310/533
摘要： The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing one or more VEGF family gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to one or more VEGF family mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine and optionally other modifications or combinations thereof. Also provided are methods of decreasing expression of one or more VEGF family gene in a cell or in a subject to treat one or more VEGF family-related disease.
摘要翻译：本公开提供能够降低或沉默一种或多种VEGF家族基因表达的meroduplex核糖核酸分子（mdRNA）。本公开的mdRNA包含至少三条链，其结合形成由切口或间隙隔开的至少两个非重叠双链区域，其中一条链与一个或多个VEGF家族mRNA互补。此外，meroduplex可以具有至少一个被5-甲基尿苷取代的尿苷和任选的其它修饰或组合。还提供减少细胞或受试者中一种或多种VEGF家族基因表达以治疗一种或多种VEGF家族相关疾病的方法。

74. 发明申请

US20090220435A1 TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS 审中-公开
标题翻译：用于增强治疗药物的粘膜递送的轻度结节调节肽组分
公开(公告)号：US20090220435A1
公开(公告)日：2009-09-03
申请号：US11997132
申请日：2006-07-27
申请人： Steven C. Quay , Shu-Chih Chen Quay , Kunyuan Cui , Anthony P. Sileno , Paul Hickok Johnson , Michael E. Houston , Henry R. Costantino , Michael V. Templin
发明人： Steven C. Quay , Shu-Chih Chen Quay , Kunyuan Cui , Anthony P. Sileno , Paul Hickok Johnson , Michael E. Houston , Henry R. Costantino , Michael V. Templin
IPC分类号： A61K9/12 , A61K38/21 , A61K38/20 , A61K39/395 , A61K39/00 , A61K38/28 , A61K38/10 , A61K38/16 , A61K31/7088 , A61K31/60 , A61K31/56 , A61K31/485 , C07K14/00 , C07K7/00
CPC分类号： C07K14/00 , A61K9/0043 , A61K31/55 , A61K38/12 , A61K38/22 , A61K38/23 , A61K45/06 , A61K47/42 , A61K47/60 , A61K2300/00
摘要： Compounds and components including sequences for mucosal epithelial transport of an active agent are given. Tight junction modulating peptide components are described for use in transport and delivery. Permeability can be enhanced with reversibility. Compounds and components for enhanced delivery may be peptide or protein variants, conjugates, or other analog types and structures.
摘要翻译：给出了包括活性剂粘膜上皮转运序列的化合物和组分。描述了紧密连接调节肽组分用于运输和递送。渗透性可以提高可逆性。用于增强递送的化合物和组分可以是肽或蛋白质变体，缀合物或其它类似物和结构。

75. 发明申请

US20080287383A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB GENE EXPRESSION AND USES THEREOF 审中-公开
标题翻译：用于抑制ERBB基因表达的核酸化合物及其用途
公开(公告)号：US20080287383A1
公开(公告)日：2008-11-20
申请号：US12039658
申请日：2008-02-28
申请人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Mohammad Ahmadian
发明人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Mohammad Ahmadian
IPC分类号： A61K31/7105 , C07H21/02 , A61P35/00
CPC分类号： C12N15/1135 , C12N15/1137 , C12N15/1138 , C12N2310/14
摘要： The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing ERBB gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an ERBB mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of an ERBB gene in a cell or in a subject to treat an ERBB-related disease.
摘要翻译：本公开提供能够降低或沉默ERBB基因表达的meroduplex核糖核酸分子（mdRNA）。本公开的mdRNA包含至少三条链，其结合形成由切口或间隙分开的至少两个不重叠的双链区域，其中一条链与ERBB mRNA互补。此外，meroduplex可以具有至少一个用5-甲基尿苷取代的尿苷，被锁定的核酸替代的核苷，或任选的其它修饰，以及它们的任何组合。还提供减少细胞或受试者中ERBB基因表达以治疗ERBB相关疾病的方法。

76. 发明申请

US20070254362A1 COMPOSITIONS AND METHODS EMPLOYING UNIVERSAL-BINDING NUCLEOTIDES FOR TARGETING MULTIPLE GENE VARIANTS WITH A SINGLE siRNA DUPLEX 审中-公开
标题翻译：组合物和方法采用通用结合核酸，用单克隆双链体靶向多种基因变异体
公开(公告)号：US20070254362A1
公开(公告)日：2007-11-01
申请号：US11610403
申请日：2006-12-13
申请人： Steven C. Quay , James Anthony McSwiggen
发明人： Steven C. Quay , James Anthony McSwiggen
IPC分类号： C12N5/06 , C07H21/02
CPC分类号： C12N15/111 , C12N15/113 , C12N2310/14 , C12N2310/321 , C12N2310/33 , C12N2310/331 , C12N2320/50 , C12N2320/51 , C12N2310/3521
摘要： Provided are siRNA molecules of between about 15 base-pairs and about 40 base-pairs comprising one or more universal-binding nucleotide such as inosine, 1-β-D-ribofuranosyl-5-nitroindole, and 1-β-D-ribofuranosyl-3-nitropyrrole, compositions comprising one or more universal-binding nucleotide comprising siRNA, and methods for making and for using such universal-binding nucleotide comprising siRNA molecules to increase the specific binding of the modified siRNA molecule to variants of a target sequence such as, for example, when in contact with a biological sample and to reduce off-target effects of the siRNA molecule.
摘要翻译：提供包含一个或多个通用结合核苷酸如肌苷，1-β-D-呋喃核糖-5-硝基吲哚和1-β-D-呋喃核糖基-5-硝基吲哚之间的约15个碱基对和约40个碱基对的siRNA分子。 3-硝基吡咯，包含一种或多种包含siRNA的通用结合核苷酸的组合物，以及用于制备和使用包含siRNA分子的通用结合核苷酸的方法，以增加修饰的siRNA分子与靶序列变体的特异性结合，例如当与生物样品接触并且减少siRNA分子的脱靶效应时。

77. 发明授权

US06887210B2 Devices and methods for obtaining mammary fluid samples for evaluating breast diseases, including cancer 失效
标题翻译：用于获得用于评估乳腺疾病（包括癌症）的乳液样品的装置和方法
公开(公告)号：US06887210B2
公开(公告)日：2005-05-03
申请号：US10002540
申请日：2001-11-13
申请人： Steven C. Quay
发明人： Steven C. Quay
IPC分类号： G01N33/48 , A61B5/00 , A61B10/00 , A61B10/02 , A61M1/06 , C12Q1/04 , B65D81/00
CPC分类号： C12Q1/6886 , A61B5/14546 , A61B10/0041 , A61B10/0045 , A61B10/0096 , A61M1/06 , A61M1/064 , A61M1/066 , A61M2205/075
摘要： Biological samples of mammary fluid or components thereof are obtained using a breast pump device coupled with a solid phase sample collection medium, alternatively facilitated by administering oxytocin to the subject. The breast pump device stimulates expression of mammary fluid and provides for collection of diagnostic samples to evaluate breast disease, including cancer. The biological sample may include whole cells or cellular components, purified or bulk proteins, glycoproteins, peptides, nucleotides or other desired constituents comprising a breast disease marker. Methods, kits and adapter devices relating to the breast pump device are also provided. Yet additional methods, devices, accessories, and materials are provided for laboratory handling and processing of breast fluid samples and for related diagnostic methods.
摘要翻译：使用与固相样品收集介质偶联的吸乳器装置获得乳液或其组分的生物样品，或者通过向受试者施用催产素来辅助。乳房泵装置刺激乳腺液的表达，并提供收集诊断样品以评估乳腺疾病，包括癌症。生物样品可以包括全细胞或细胞组分，纯化或体蛋白，糖蛋白，肽，核苷酸或包含乳腺疾病标记的其它所需组分。还提供了与吸奶器装置相关的方法，套件和适配器装置。还提供了其他方法，设备，附件和材料，用于乳液样品的实验室处理和加工以及相关的诊断方法。

78. 发明授权

US06727280B2 Method for treating colorectal carcinoma using a taxane/tocopherol formulation 失效
标题翻译：使用紫杉烷/生育酚制剂治疗结直肠癌的方法
公开(公告)号：US06727280B2
公开(公告)日：2004-04-27
申请号：US10188289
申请日：2002-07-01
申请人： Nagesh Palepu , Dean Kessler , Alexander K. Tustian , Steven C. Quay , Panayiotis P. Constantinides , Karel J. Lambert
发明人： Nagesh Palepu , Dean Kessler , Alexander K. Tustian , Steven C. Quay , Panayiotis P. Constantinides , Karel J. Lambert
IPC分类号： A61K3121
CPC分类号： A61K9/1075 , A61K9/0019 , A61K9/4858 , A61K47/22
摘要： The present invention provides methods for administering a taxane composition for the treatment of cancer. In one aspect, the compositions are not diluted prior to administration. Some embodiments provide methods for administering a taxane as a bolus injection or an intravenous infusion in less than about 30 minutes. In other aspects, the invention provides methods for administering a taxane to provide high concentrations of the taxane in blood or in tumors. Another aspect provides methods for administering a taxane to provide anti-tumor activities against solid tumors. In some embodiments, the methods provide anti-tumor activities against tumors that were resistant to conventional taxane administration methods. In some embodiments, the methods provide anti-tumor activities against colorectal tumors.
摘要翻译：本发明提供了用于治疗癌症的紫杉烷组合物的方法。在一个方面，组合物在施用前不经稀释。一些实施方案提供了在少于约30分钟内施用紫杉烷作为推注或静脉内输注的方法。在其他方面，本发明提供了用于施用紫杉烷以在血液或肿瘤中提供高浓度紫杉烷的方法。另一方面提供了用于施用紫杉烷以提供抵抗实体瘤的抗肿瘤活性的方法。在一些实施方案中，所述方法提供对常规紫杉烷给药方法有抗性的针对肿瘤的抗肿瘤活性。在一些实施方案中，所述方法提供针对结肠直肠肿瘤的抗肿瘤活性。

79. 发明授权

US06660286B1 Emulsion vehicle for poorly soluble drugs 失效
标题翻译：用于难溶性药物的乳剂
公开(公告)号：US06660286B1
公开(公告)日：2003-12-09
申请号：US09317499
申请日：1999-05-24
申请人： Karel J. Lambert , Panayiotis P. Constantinides , Alexander K. Tustian , Steven C. Quay
发明人： Karel J. Lambert , Panayiotis P. Constantinides , Alexander K. Tustian , Steven C. Quay
IPC分类号： A01K9107
CPC分类号： A61K47/22 , A61K9/0019 , A61K9/1075 , A61K9/4858 , Y10S514/938 , Y10S514/975 , Y10S977/775 , Y10S977/801 , Y10S977/907 , Y10S977/915
摘要： An emulsion of tocopherol incorporating a co-solvent and, stabilized by biocompatible surfactants, as a vehicle or carrier for therapeutic drugs, which is substantially ethanol free and which can be administered to animals or humans by various routes is disclosed. Also included in the emulsion is PEGylated vitamin E. PEGylated &agr;-tocopherol includes polyethylene glycol subunits attached by a succinic acid diester at the ring hydroxyl of vitamin E and serves as a primary surfactant, stabilizer and a secondary solvent in emulsions of &agr;-tocopherol.
摘要翻译：公开了一种包含共溶剂并通过生物相容性表面活性剂稳定化的生育酚乳剂作为治疗药物的载体或载体，其基本上不含有乙醇，并且可通过各种途径施用于动物或人类。乳液中还包含聚乙二醇化维生素E.聚乙二醇化α-生育酚包括在维生素E的环羟基处由琥珀酸二酯连接的聚乙二醇亚单位，并且用作α-生育酚乳液中的主要表面活性剂，稳定剂和第二溶剂。

80. 发明授权

US06620404B1 Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media 失效
标题翻译：气体超声造影剂和用于选择用作超声波造影剂的气体的方法
公开(公告)号：US06620404B1
公开(公告)日：2003-09-16
申请号：US09670894
申请日：2000-09-28
申请人： Steven C. Quay
发明人： Steven C. Quay
IPC分类号： A61K9133
CPC分类号： A61K49/223
摘要： Disclosed herein are agents for enhancing the contrast in an ultrasound image. These agents are extremely small bubbles, or “microbubbles,” comprised of specially selected gases. The microbubbles described herein exhibit long life spans in solution and may be produced at a size small enough to traverse the lungs, thus enabling improved ultrasound imaging of the cardiovascular system and other vital organs. Also disclosed herein is a method for selecting gases from which contrast agents may be produced. The method is based on calculations using inherent physical properties of gases and describes a means to associate the properties of a gas with the time for dissolution of microbubbles comprised of the gas.
摘要翻译：本文公开了用于增强超声图像中的对比度的试剂。这些试剂是非常小的气泡，或由特殊选择的气体组成的“微泡”。本文描述的微泡在溶液中显示出长寿命，并且可以以足够小的尺寸产生穿过肺，从而能够改善心血管系统和其他重要器官的超声成像。本文还公开了用于选择可以从其中产生造影剂的气体的方法。该方法基于使用气体的固有物理性质的计算，并且描述了将气体的性质与由气体组成的微泡溶解的时间相关联的手段。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式